Shopping Cart
Remove All
Your shopping cart is currently empty
A-366 is a highly selective peptide-competitive histone methyltransferase G9a inhibitor with IC50s of 3.3 and 38 nM for G9a and GLP, respectively.It is more than 1,000-fold selective for G9a and GLP over the other 21 methyltransferases. It is an inhibitor of the Spindlin1-H3K4me3 interaction with an IC50 of 182.6 nM.It exhibits high affinity for human H3R with a Ki value of 17 nM, and shows subtype selectivity between subgroups of the histaminergic and dopaminergic receptor families.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | - | In Stock | |
| 2 mg | $43 | - | In Stock | |
| 5 mg | $68 | In Stock | In Stock | |
| 10 mg | $92 | In Stock | In Stock | |
| 25 mg | $219 | - | In Stock | |
| 50 mg | $378 | Backorder | Backorder | |
| 100 mg | $558 | Backorder | Backorder | |
| 1 mL x 10 mM (in DMSO) | $75 | - | In Stock |
| Description | A-366 is a highly selective peptide-competitive histone methyltransferase G9a inhibitor with IC50s of 3.3 and 38 nM for G9a and GLP, respectively.It is more than 1,000-fold selective for G9a and GLP over the other 21 methyltransferases. It is an inhibitor of the Spindlin1-H3K4me3 interaction with an IC50 of 182.6 nM.It exhibits high affinity for human H3R with a Ki value of 17 nM, and shows subtype selectivity between subgroups of the histaminergic and dopaminergic receptor families. |
| Targets&IC50 | G9a/GLP:3.3 nM |
| In vitro | For tumor cell growth, A-366 had less toxic effects than some other G9a/GLP small molecule compound inhibitors, and no difference in the methylation effect on H3K9me2. Various leukemia cell lines were treated with A-366 in vitro, and these tumor cells would produce significant differentiation and morphological changes. |
| In vivo | For tumor cell growth, A-366 had less toxic effects than some other G9a/GLP small molecule compound inhibitors, and no difference in the methylation effect on H3K9me2. Various leukemia cell lines were treated with A-366 in vitro, and these tumor cells would produce significant differentiation and morphological changes. |
| Kinase Assay | 7.5× compounds are added to a 96-well PolyPlate containing 60 μL of Buffer per well with substrates CoA (200 μM), ATP (400 μM), and [14C]citrate. Reaction is started with 4 μL (300 ng/well) ACL, and the plate is incubated at 37°C for 3 h. Th |
| Cell Research | PC-3 prostate adenocarcinoma cells are incubated in triplicate with DMSO or the indicated concentrations of A-366 or UNC0638 for 72 hours. H3K9me2 levels are assessed by In-Cell Western assay. (Only for Reference) |
| Synonyms | A366, A 366 |
| Molecular Weight | 329.44 |
| Formula | C19H27N3O2 |
| Cas No. | 1527503-11-2 |
| Smiles | COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |
| Relative Density. | 1.29 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 32.9 mg/mL (99.87 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.07 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.